Introduction: Acute myelogenous leukemia (AML) is a genetically heterogeneous disease.
Yet current therapy has changed little over the decades and includes the nucleoside analog …

Isocitrate dehydrogenases 1 and 2 (IDH1/2) are homodimeric enzymes that catalyze the
conversion of isocitrate to α-ketoglutarate (α-KG) in the tricarboxylic acid cycle. However …

Nobiletin, a dietary citrus flavonoid, has been reported to possess several biological
activities such as antioxidant, anti-inflammatory, and anticancer properties. The aim of this …

Highly Commended in the category of Oncology at the British Medical Association Awards
2019 The accessible guide to the principles behind new, more targeted drug treatments for …

Background The aim of this study is to find the potential survival related DNA methylation
signature capable of predicting survival time for acute myelocytic leukemia (AML) patients …

Background: Cytarabine (Ara-C) is the primary drug in different treatment schemas for acute
myeloid leukemia (AML) and requires the human equilibrative nucleoside transporter …

Despite the tremendous progress made in the comprehension of acute myeloid leukemia
(AML) over the last 30 years most patients die from their disease. Our understanding of AML …

The correlation between the expression levels of p65 and TNF-α in patients with acute
myelocytic leukemia (AML) and AML cell lines were investigated. The bone marrow samples …

Aim: The cytogenetic and molecular features of leukemia cells are chief predictors of survival
in acute myeloid leukemia (AML). However, treatment outcomes in AML differ between low …

Acute myeloid leukemia (AML) is a heterogeneous condition characterized by clonal
proliferation of myeloid precursors and accumulation of leukemic blasts in the bone marrow …